CELLINI, CLAUDIA
 Distribuzione geografica
Continente #
NA - Nord America 829
EU - Europa 557
AS - Asia 281
AF - Africa 46
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.715
Nazione #
US - Stati Uniti d'America 829
GB - Regno Unito 164
SE - Svezia 110
CN - Cina 99
DE - Germania 74
SG - Singapore 73
VN - Vietnam 66
IT - Italia 48
UA - Ucraina 48
IE - Irlanda 28
IN - India 26
TG - Togo 24
FR - Francia 21
RU - Federazione Russa 19
ZA - Sudafrica 14
BG - Bulgaria 11
EE - Estonia 9
FI - Finlandia 7
JO - Giordania 7
BE - Belgio 5
SC - Seychelles 5
CH - Svizzera 4
IR - Iran 4
CI - Costa d'Avorio 3
GR - Grecia 3
LB - Libano 3
NL - Olanda 3
JP - Giappone 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
EU - Europa 1
PH - Filippine 1
PL - Polonia 1
PT - Portogallo 1
Totale 1.715
Città #
Southend 141
Fairfield 102
Chandler 97
Singapore 67
Ashburn 63
Wilmington 51
Woodbridge 50
Houston 44
Seattle 44
Dong Ket 42
Cambridge 39
Ann Arbor 36
Jacksonville 34
Santa Clara 30
Princeton 29
Dublin 28
Boardman 25
Lomé 24
Nanjing 14
Bremen 13
Padova 13
Westminster 13
Beijing 12
Sofia 11
Berlin 10
Turin 8
Amman 7
San Diego 7
Hangzhou 6
Helsinki 6
New York 6
Brussels 5
Hebei 5
Jinan 5
Kunming 5
Mahé 5
Nanchang 5
Zhengzhou 5
Changsha 4
Jiaxing 4
Leawood 4
Mülheim 4
Redwood City 4
Saint Petersburg 4
Shanghai 4
Shenyang 4
Verona 4
Abidjan 3
Andover 3
Bern 3
Falls Church 3
Guangzhou 3
Norwalk 3
Tianjin 3
Bologna 2
Chengdu 2
Dearborn 2
Falkenstein 2
Florence 2
Hyderabad 2
Medford 2
Meppel 2
Milan 2
Olalla 2
Phoenix 2
Redmond 2
Tokyo 2
Zanjan 2
Augusta 1
Bühl 1
Changchun 1
Costa Mesa 1
Dongguan 1
Foshan 1
Frankfurt am Main 1
Fremont 1
Fuzhou 1
Groningen 1
Harbin 1
Hefei 1
Henderson 1
Kiev 1
Lanzhou 1
Lappeenranta 1
London 1
Los Angeles 1
Lyon 1
Mason 1
Monmouth Junction 1
Moscow 1
Mountain View 1
Muizenberg 1
Munich 1
Paris 1
Portland 1
Prescot 1
Pune 1
San Francisco 1
San Venanzo 1
Shijiazhuang 1
Totale 1.224
Nome #
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 190
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 172
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 145
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 145
Assessmen of disease ativity in multiple myeloma with FDG-PET imaging 143
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 134
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 128
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 123
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 120
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 120
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 113
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 107
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 100
Totale 1.740
Categoria #
all - tutte 4.337
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.337


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020300 0 0 0 0 0 50 48 57 56 39 25 25
2020/2021254 49 12 5 23 6 14 1 12 15 18 13 86
2021/2022288 15 6 27 24 30 19 8 18 7 28 57 49
2022/2023386 40 75 19 57 19 36 11 15 52 13 32 17
2023/202475 5 12 7 7 8 21 3 0 2 3 3 4
2024/2025163 6 48 25 17 46 21 0 0 0 0 0 0
Totale 1.740